Zacks Research Issues Pessimistic Estimate for BMY Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Equities researchers at Zacks Research dropped their Q4 2026 EPS estimates for shares of Bristol Myers Squibb in a note issued to investors on Tuesday, January 20th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings of $1.32 per share for the quarter, down from their previous estimate of $1.33. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s Q2 2027 earnings at $1.56 EPS.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.52 by $0.11. The business had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The firm’s revenue was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS.

Several other research firms also recently commented on BMY. Citigroup reiterated a “neutral” rating and issued a $53.00 target price (up from $45.00) on shares of Bristol Myers Squibb in a research report on Wednesday, January 7th. Truist Financial set a $65.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, December 3rd. Guggenheim reissued a “buy” rating on shares of Bristol Myers Squibb in a report on Tuesday, December 23rd. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $57.00 price target (up previously from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Seven investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Bristol Myers Squibb has an average rating of “Hold” and a consensus target price of $56.86.

Bristol Myers Squibb Trading Up 0.7%

NYSE BMY opened at $54.86 on Thursday. The company has a market cap of $111.68 billion, a price-to-earnings ratio of 18.53, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $63.33. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. The business’s fifty day moving average is $52.41 and its 200 day moving average is $48.33.

Institutional Trading of Bristol Myers Squibb

A number of large investors have recently bought and sold shares of BMY. Trifecta Capital Advisors LLC acquired a new stake in Bristol Myers Squibb during the second quarter worth approximately $25,000. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Harbor Capital Advisors Inc. increased its stake in shares of Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 313 shares in the last quarter. REAP Financial Group LLC increased its stake in shares of Bristol Myers Squibb by 202.8% in the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 428 shares in the last quarter. Finally, KERR FINANCIAL PLANNING Corp bought a new position in Bristol Myers Squibb in the third quarter worth approximately $35,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be paid a dividend of $0.63 per share. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a yield of 4.6%. The ex-dividend date of this dividend is Friday, January 2nd. Bristol Myers Squibb’s payout ratio is 85.14%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Strategic oncology collaboration: BMY struck a deal with Janux to develop a cancer drug, a collaboration that could add pipeline value and follow‑on revenue potential if milestones are met; the transaction is reported at up to ~$800–850M in total consideration. Janux & Bristol Myers deal Reuters
• Positive Sentiment: AI and early detection push: BMY announced a collaboration with Microsoft to advance AI‑driven early lung cancer detection — a move that could expand diagnostic/real‑world evidence capabilities and support earlier use of oncology assets. BMY-Microsoft AI lung cancer collaboration
• Positive Sentiment: Regulatory/market expansion for Opdivo: New recommended NHS adoption of Opdivo in early lung cancer (UK) supports continued uptake of an established oncology franchise and associated revenues. Opdivo adoption in UK
• Positive Sentiment: Bullish analyst flow: UBS upgraded BMY to Buy, highlighting a favorable risk/reward; other firms (Leerink) are also upbeat on pipeline optionality — supportive for sentiment and flows. UBS upgrade Yahoo
• Positive Sentiment: Pipeline narrative reinforced: Analyst commentary (Zacks) highlights a deep late‑stage pipeline and encouraging early uptake of the new schizophrenia drug Cobenfy — underscores multi‑year growth optionality. Zacks pipeline piece
• Neutral Sentiment: Small analyst estimate moves: Zacks issued minor tweaks to quarterly EPS estimates (small ups and downs across Q4/Q1/Q2 FY26–27); these are modest adjustments rather than large swings to guidance. MarketBeat BMY summary
• Neutral Sentiment: Clinical study updates: BMY provided a KarXT long‑term urological safety study update — important for investor monitoring of psychiatric franchise risks/rewards but not an immediate revenue event. TipRanks KarXT study
• Neutral Sentiment: Media & TV coverage: BMY was mentioned on finance shows (CNBC Fast Money), which can lift intraday volume but rarely shifts fundamentals by itself. CNBC Fast Money clip
• Negative Sentiment: Short‑term pressure and pullback commentary: Coverage flagged a recent ~3% pullback and noted potential institutional rebalancing — signals that supply or profit‑taking could weigh near term if sentiment cools. Yahoo pullback article
• Negative Sentiment: Minor downward EPS revisions for FY27/Q1 by some desks: A few small cuts to FY2027 and near‑term quarter estimates were reported — modest headwinds to near‑term EPS visibility. MarketBeat BMY estimates

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.